Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may guide depression treatment

NCT ID NCT07269886

Knowledge-focused Sponsor: Neomente SAS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving doctors extra information from a blood test and genetics could help them choose better medications for people with depression. 79 adults with moderate to severe depression took part. Half of the doctors received this extra information, while the other half provided standard care. The study measured how much depression symptoms improved after 8 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

79 people

The number who actually took part.

Started

Aug 2022

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Urban depressive outpatients from the City of Buenos Aires were recruited. The population of Buenos Aires is predominantly of Caucasian origin, mainly with ancestry from Italy and Spain.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Being male or female, aged 18-65. 2. Having a current DSM-5 diagnosis of non-psychotic Major Depressive Disorder confirmed by SCID. 3. Having moderate to severe depressive symptoms as measured by the HAM-D-17. 4. Being indicated for pharmacotherapy for Major Depressive Disorder. 5. Providing written informed consent (signed and dated). \- Exclusion Criteria: 1. Having a current or past diagnosis of bipolar disorder or psychotic disorders. 2. Having a moderate to severe substance use disorder within the past six months. 3. Having active suicidal ideation. 4. Having a neurocognitive disorder. 5. Having an unstable or decompensated medical illness likely to confound study outcomes. 6. Being pregnant or lactating. 7. Having known contraindications to the indicated antidepressant classes. 8. Being unable to provide informed consent. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression - major depressive disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression - major depressive disorder

Contacts and locations

Locations

  • Neomente

    Buenos Aires, 1425, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.